About Lungpacer
Lungpacer is a private company based in Exton, Pennsylvania. It has reported $141,215,550 raised in seven offerings on Form D since June 2017. Its chief executive is Douglas Evans.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Sep 30, 2026 | Oct 14, 2026 | $7,833,333of $30.0M target | 2 | $3.9M | Debt, Unsecured Convertible Promissory NotesRule 506(b) | Form D ↗ |
| Apr 23, 2026 | Apr 28, 2026amended Oct 8, 2026 | $12,000,000of $20.0M target | 2 | $6.0M | Debt, Unsecured Convertible Promissory NotesRule 506(b) | Form D/A ↗2 earlier filings |
| Mar 18, 2025 | Apr 1, 2025 | $10,000,000fully sold | 2 | $5.0M | Debt, Secured Convertible Promissory NotesRule 506(b) | Form D ↗ |
| Apr 6, 2022 | Apr 19, 2022 | $20,000,064of $30.0M target | 4 | $5.0M | Equity, Series 1 Class B Preferred Stock FinancingRule 506(b) | Form D ↗ |
| Dec 22, 2020 | Jan 6, 2021amended Dec 13, 2022 | $15,999,984of $21.0M target | 3 | $5.3M | Equity, Class B Preferred Stock FinancingRule 506(b) | Form D/A ↗2 earlier filings |
| Apr 30, 2019 | May 14, 2019 | $55,757,518of $65.0M target | 8 | $6.9M | Equity, Class B Preferred Stock and conversion of NotesRule 506(b) | Form D ↗ |
| May 24, 2017 | Jun 9, 2017 | $19,624,651fully sold | 15 | $1.3M | Equity, Series A Preferred Stock FinancingRule 506(b) | Form D ↗ |
| Total, seven offerings | $141,215,550 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Lungpacer's Form D filed Oct 14, 2026.
Earlier filings also listed Rosemarie Dhavale (executive officer, last listed Apr 2025), Nawzer Mehta (senior vice president, clinical affairs, last listed Dec 2022), Karen Long (director, last listed Dec 2022), Josh Makower (director, last listed Dec 2022), Jose Gordo (director, last listed Dec 2022), Valeska Schroeder (director, last listed Apr 2022), Lesley Fronio (chief commercial officer, last listed Apr 2022) and Michael Favet (director, last listed May 2019).